Table 4 Secondary Outcomes by Study
From: Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
Study | Hospitalization Duration | Fever Duration | Days to fever resolution | NonSerious Adverse Events | Serious Adverse Events | Death | |
|---|---|---|---|---|---|---|---|
2nd IVIg (2 g/kg) median (range) | Son et al. | 6 (2–20) | 10 (5–37) | NR | 3/86 (3%) | 1/86 (1%) | 1/86 (1%) |
Youn et al. | 10 (8–12) | total NR | 0.71 (0.17–2.6) | 5/32 (16%) | 0/32 (0%) | 0/32 (0%) | |
Teraguchi et al. | NR | 10 (6–14) | 1 (1–3) | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) | |
Furukawa et al. | NR | total NR | NR | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) | |
Ogata et al. | mean 12 ± 2.1 | mean 11 ± 2 | mean 3 ± 2.4 | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) | |
Miura et al. (2005) | NR | NR | NR | 2/11 (18%) | 0/11 (0%) | 0/11 (0%) | |
Miura et al. (2011) | NR | NR | NR | 0/74 (0%) | 0/74 (0%) | 0/74 (0%) | |
Total | – | – | – | 10/263 (4%, [95% CI: 2–7%]) | 1/263 (0.4%, [95% CI: 0–2%]) | 1/263 (0.4%, [95% CI: 0–2%]) | |
IVMP (30 mg/kg/d × 3 d) median (range) | Teraguchi et al. | NR | 9.5 (7–18) | < 24 h | 1/14 (7%) | 0/14 (0%) | 0/14 (0%) |
Furukawa et al. | NR | total NR | NR | 11/44 (25%) | 1/44 (2%) | 0/44 (0%) | |
Ogata et al. | mean 14.5 ± 2 | mean 8 ± 2.1 | mean 1 ± 1.3 | 2/13 (15%) | 0/13 (0%) | 0/13 (0%) | |
Miura et al. (2005) | NR | NR | NR | 6/11 (55%) | 0/11 (0%) | 0/11 (0%) | |
Total | – | – | – | 20/82 (24%, [95% CI: 16–35%]) | 1/82 (1%, [95% CI: 0–7%]) | 0/82 (0%, [95% CI: 0–4%]) | |
IFX (5–7 mg/kg ×1) median (range) | Son et al. | 5.5 (4–35) | 8 (5–14) | NR | 6/20 (30%) | 0/20 (0%) | 0/20 (0%) |
Youn et al. | 8 (7–9) | total NR | 0.25 (0.08–1) | 1/11 (9%) | 0/11 (0%) | 0/11 (0%) | |
Singh et al. | NR | NR | NR | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) | |
– | – | – | 7/43 (16%, [95% CI: 7–31%]) | 0/43 (0%, [95% CI: 0–8%]) | 0/43 (0%, [95% CI: 0–8%]) |